Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease (TRUST-2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01279577 |
Recruitment Status :
Completed
First Posted : January 19, 2011
Last Update Posted : February 10, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will run in centers in Germany, Denmark, Austria, Czech Republic, and Switzerland, only.
This proof-of-concept study aims to evaluate the efficacy of three doses of oral TSO suspension vs. placebo for the induction of remission in Crohn's disease.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn´s Disease | Drug: Low dose TSO Drug: Medium dose TSO Drug: High dose TSO Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 254 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease |
Study Start Date : | November 2010 |
Actual Primary Completion Date : | February 2014 |
Actual Study Completion Date : | February 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Low dose TSO
Low dose suspension of TSO
|
Drug: Low dose TSO
Low dose TSO suspension |
Experimental: Medium dose TSO
Medium dose suspension of TSO
|
Drug: Medium dose TSO
Medium dose TSO suspension |
Experimental: High dose TSO
High dose suspension of TSO
|
Drug: High dose TSO
High dose TSO suspension |
Placebo Comparator: Placebo
Placebo solution
|
Drug: Placebo
Placebo solution |
- Rate of clinical remission at week 12 (LOCF) defined as a CDAI< 150 [ Time Frame: 12 weeks ]
- Reduction of > 100 points in CDAI [ Time Frame: 12 weeks ]
- Adverse events [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Major Inclusion Criteria:
- Signed informed consent,
- Man or woman between 18 and 75 years of age,
- Established diagnosis of Crohn's disease (CD) since at least 3 months prior to screening confirmed by endoscopic and histological, or endoscopic and radiological criteria,
- Negative pregnancy test in females of childbearing potential.
Major Exclusion Criteria:
- Bowel surgery within the last 3 months prior to baseline,
- Resection of more than 50 cm of the ileum,
- Ileostomy or colostomy,
- Septic complications,
- Evidence of infectious diarrhoea (i.e., pathogenic bacteria or Clostridium difficile toxin in stool culture),
- Abscess, perforation, fistulas, or perianal lesions,
- Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
- Clinical signs of stricturing disease,
- Parenteral or tube feeding,
- Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal [ULN] at screening), liver cirrhosis, or portal hypertension,
- Abnormal renal function (Cystatin C > ULN) at screening,
- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results,
- Any condition associated with significant immunosuppression,
- Active malignancy or treatment with anticancer drugs during the last 5 years.
- Existing or intended pregnancy or breast-feeding,
- Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01279577
Germany | |
Klinikum der Johann Wolfgang Goethe-Universität | |
Frankfurt a.M., Hessen, Germany, 60590 |
Principal Investigator: | Jürgen Schölmerich, Prof. | Klinikum der Johann Wolfgang Goethe-Universität |
Responsible Party: | Dr. Falk Pharma GmbH |
ClinicalTrials.gov Identifier: | NCT01279577 |
Other Study ID Numbers: |
TSU-2/CDA 2006-000720-13 ( EudraCT Number ) |
First Posted: | January 19, 2011 Key Record Dates |
Last Update Posted: | February 10, 2015 |
Last Verified: | February 2015 |
Crohn´s disease Trichuris suis randomized |
placebo induction of remission porcine whipworm |
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |